

DOCKET NO.: ALZA-0142

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**George V. Guittard, et al.**

**Confirmation No.: 8204**

**Application No.: 10/645,467**

**Group Art Unit: 1616**

**Filing Date: August 20, 2003**

**Examiner: George, Konata M.**

**For: METHOD FOR MANAGEMENT OF INCONTINENCE**

**DATE OF DEPOSIT: January 13, 2006**

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Wendy A. Choi  
\_\_\_\_\_  
TYPED NAME: Wendy A. Choi  
REGISTRATION NO.: 36,697

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
  - Certification in Accordance with § 1.97(e) is attached; or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers **1 through 364** listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of reference numbers on the attached Form PTO 1449 are not required to be submitted pursuant to the waiver of 37 CFR § 1.98(a)(2)(ii).
  - Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

REMARKS

Pursuant to 37 C.F.R. § 1.98, the art identified in the appended documents and other information and matters discussed below may be helpful to the U.S. Patent and Trademark Office (PTO) in its consideration of the above-identified patent application.

ALZA Corporation, the assignee of this application, has filed a Request for Reexamination of claims 1 to 23 of related U.S. Patent No. 6,919,092 (“092 Patent”). This application is a continuation of Application No. 09/785,805, which issued as the 092 Patent. The reexamination of the 092 Patent was assigned to Examiner Evelyn Mei Huang, and has been granted.


IMPAX Laboratories, Inc. and Mylan Pharmaceuticals Inc. have both filed certificates with the U.S. Food and Drug Administration, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (“Paragraph IV Certifications”), alleging that, *inter alia*, the claims of the 092 Patent are invalid either under 35 U.S.C. § 102(b) as anticipated and/or under 35 U.S.C. § 103(a) as obvious. ALZA does not agree, and believes that the references cited in the Paragraph IV Certifications, alone or in combination, do not render claims 1 to 23 of the patent unpatentable or invalid.

In addition, IMPAX alleges in its Paragraph IV Certification that ALZA engaged in

inequitable conduct for failing to identify and disclose to the Office litigations involving U.S. Patent No. 6,124,355 and certain references that are identified in the accompanying Form PTO-1449. ALZA denies that it withheld any material information with the intent to mislead the Patent Office.

U.S. Patents Nos. 5,674,895, 5,840,754, 5,912,268, 6,124,355 (the "355 Patent"), and 6,262,115, which share a claim of priority with the instant patent application, are or have been the subject of litigation, *i.e.*, *ALZA Corporation v. IMPAX Laboratories, Inc.*, Civil Action Nos. 03-04032-VRW (N.D. Calif.), *IMPAX Laboratories v. ALZA Corporation, Inc.*, Civil Action Nos. 03-04796-VRW (N.D. Calif.) (both N.D. Calif. Cases collectively referred to as the "IMPAX Litigations"), and *ALZA Corporation v. Mylan Laboratories, Inc.*, Civil Action No. 1:03CV61 (N.D. W.Va.) ("Mylan Litigation").

The 355 Patent is a continuation-in-part of Application No. 08/806,773, filed February 26, 1997, now U.S. Patent No. 5,912,268, which is continuation-in-part of Application No. 08/706,576, filed September 5, 1996, now U.S. Patent No. 5,840,754, which is a continuation-in-part of Application 08/445,849, filed May 22, 1995, now U.S. Patent No. 5,674,895.



The only litigation to proceed to trial is the Mylan Litigation concerning the 355 Patent. Both the Mylan and IMPAX courts interpreted the 355 Patent in the same way. As discussed more fully below, a final decision has been entered in the Mylan Litigation holding the 355 Patent claims in suit invalid and not infringed, and as a result Judgment was entered in the IMPAX Litigation concerning the 355 Patent without considering the merits. The litigations concerning patents other than the 355 Patent were dismissed after ALZA granted Mylan and IMPAX covenants not to sue.

ALZA is submitting in Appendix I a Form PTO-1449 listing, *inter alia*, certain patents, printed publications, and other materials that came to the Patent Owner's attention during the above-noted litigations. A copy of each of the documents is included with the Form PTO-1449. The Examiner is requested to indicate consideration of each reference or

document with an initial in the left hand column next to each reference or document.

As is typical in a patent litigation, Mylan and IMPAX raised a wide range of different defenses relating to the scope, validity, and enforceability of the 355 Patent, all of which are vigorously disputed by ALZA, but may be relevant in some cases to the pending claims. The Court entered judgment in Mylan's and favor invalidating the 355 Patent claims in suit. During the protracted proceedings, the litigants conducted extensive discovery and there were numerous motions and memoranda filed by the litigants with respect to various issues.

To the extent not precluded by the Protective Orders entered by the respective courts in the Mylan Litigation and IMPAX Litigations, Applicants' undersigned counsel is available to immediately provide a copy of all materials generated during these litigations (note that not all constitute prior art). ALZA has made an extensive and good faith effort to present disclosure of such materials that may be relevant to the prosecution of this pending application, namely materials that may be relevant to: (1) the identification and scope of patent and printed prior art; (2) the interpretation and scope of the claims in the pending application; and (3) application of the art to the claims in the pending application.

ALZA recognizes the burden placed on the Examiner by the large volume of materials being provided pursuant to the Information Disclosure Statement. To further facilitate the Examiner's consideration of these materials, but without attempting to usurp the Examiner's opportunity to fully consider each item, ALZA has in the table in Appendix II categorized the disclosure of each document generated in the Mylan Litigation and IMPAX Litigation, which may serve as a helpful guide to direct the Examiner to certain materials that

may be relevant to specific subject matter and issues. Each document is categorized according to whether it contains a discussion or disclosure of, or reference to, one or more of the following subjects; the drug oxybutynin; controlled release delivery of drug (oxybutynin or otherwise); and Ditropan XL – naturally there is a great deal of overlap and so, to some extent, these characterizations may be partially subjective. The chart also indicates whether the document is litigation related. Finally, in the last column, where a document has been referred to in briefs and other filings submitted by the parties in the litigations, a citation is given by reference to a Tab Number. For the Examiner's convenience, the briefs and other filings referred to by Tab Number in the chart have been collected and submitted in the bound volumes accompanying this Supplemental Information Disclosure Statement.


ALZA also submits herewith the Post-Trial Memorandum Opinion and Order that the District Court recently issued in the Mylan Litigation; this document is also listed on the enclosed Form PTO-1449. Although the District Court held the claims of the 355 Patent to be invalid in view of certain references, ALZA does not believe that this holding is relevant to examination of the pending claims. Indeed, the respective claims of the 355 Patent and the above-identified patent application differ from one another, as is apparent from even a cursory review. For example, representative pending claim 32 of the above-identified patent application is directed to a method for treating involuntary incontinence by orally admitting to a patient a sustained release, once-day dosage form of 5-250 mg of oxybutynin or its salt to provide a plasma ratio of oxybutynin/desethylmetabolite greater than about 0.18. The ratio of oxybutynin/desethylmetabolite is not recited in any claim of the 355 Patent. Similarly, pending claims 33 to 43 refer to a specific range of ratios of oxybutynin/desethylmetabolite that is not recited in the 355 Patent claims. Thus, although ALZA wishes to make the Post-Trial

Memorandum Opinion and Order of record for purposes of full disclosure, it is not believed to be relevant to patentability of the claims of the above-identified patent application.

ALZA respectfully requests that the Examiner indicate consideration of each reference or document with an initial in the left hand column next to each reference or document.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: **January 13, 2006**

  
Wendy A. Choi  
Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2006 WW



<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>1</b>	Data Processed Using Dissprof Program (V1.1), Oxybutynin C1, <b>Joint Exhibit 25</b> , November 24, 2003 MYLAN 1014396-1014492	
	<b>2</b>	Skelly, J.P. et al., "In Vitro and In Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms", <i>Pharmaceutical Research</i> , 1990, 7(9), 975-977, <b>Joint Exhibit 67</b>	
	<b>3</b>	Theeuwes, F. et al., "Osmotic Delivery Systems for the $\beta$ -Adrenoceptor Antagonists Metoprolol and Oxprenolol: Design and Evaluation of Systems for Once-Daily Administration, <i>Br. J. Clin. Pharmac.</i> , 1985, 19, 695-765, <b>Joint Exhibit 81</b>	
	<b>4</b>	Oxybutynin, ALZA/TDC Meeting, Friday July 15, 1993, Palo Alto, Ca. <b>Defendant's Exhibits DX 00028</b> , DXL-016926 thru DXL-016976	
	<b>5</b>	Ballard, B.E., "Prolonged-Action Pharmaceuticals", Chapter 91, <b>Defendant's Exhibit DX 00403</b> , 1594-1613	
	<b>6</b>	Corrigan, O.I. et al., "Influence of Dissolution Medium Buffer Composition on Ketoprofen Release from ER Products and in Vitro—in Vivo Correlation", <i>International Journal of Pharmaceutics</i> , 2003, 147-154, <b>Defendant's Exhibit DX 00408</b>	
	<b>7</b>	Frick, A. et al., "Biopharmaceutical Characterization of Oral Controlled/Modified-Release Drug Products. In Vitro/in Vivo Correlation of Roxatidine", <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 1998, 46, 313-319, <b>Defendant's Exhibits DX 00411</b>	
	<b>8</b>	Drug Class Review on Urinary Incontinence Drugs", Final Report, February 2003, Oregon Health & Science University, <b>Defendant's Exhibit DX 00431</b>	
	<b>9</b>	Oregon Health Resources Commission, Urinary Incontinence (Update Report) <b>Update #1, March 2004</b> , 12 pages, <b>Defendant's Exhibit DX 00432</b>	
	<b>9B</b>	Ouslander, J.G. et al., "Pharmacokinetics and Clinica Effects of Oxybutynin in Geriatric Patients", <i>The Journal of Urology</i> , 1988, 140, 47-50, <b>Defendant's Exhibit DX 00433</b>	
	<b>10</b>	Qiu, Y. et al., "Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium II: Development of a Predictive In Vitro Drug Release Method", <i>Journal of Pharmaceutical Sciences</i> , November 2003, 92(11), 2317-2325, <b>Defendant's Exhibit DX 00437</b>	
EXAMINER		DATE CONSIDERED	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>11</b>	ALZA Communication Exchange, A.C.E. Briefing, "The Making of Ditropan® XL: An Epic Celebrating the Cast of ALZAns who made it Happen, from 1993 to Today", <b>January 20, 1999</b> , DXL-063089 thru DXL-063100, <b>Defendant's Exhibit DX 00448</b> ,	
	<b>12</b>	Theeuwes, et al., "Elementary Osmotic Pump for Indomethacin", <i>Journal of Pharmaceutical Sciences</i> , <b>March 1983</b> , 72(3), 253-258, <b>Defendant's Exhibit DX 00450</b>	
	<b>12A</b>	Thuroff, J.W. et al., "Randomized, Double-Blind, multicenter Trial on Treatment of Frequency, Urgency and Incontinence related to Detrusor Hyperactivity: Oxybutynin Versus Propantheline Versus Placebo", <i>The Journal of Urology</i> , <b>April 1991</b> , 145, 813-817, <b>Defendant's Exhibit DX 00453</b>	
	<b>13</b>	Welling, P.G., "In Vitro Methods to Determine Bioavailability: In Vitro-In Vivo Correlations", 223 thru 232, <b>Defendant's Exhibits DX 00462</b>	
	<b>14</b>	Executive Summary, OROS® (Oxybutynin Chloride) CPC-1, <b>October 1997</b> , DXL-031021 thru DXL-063202, <b>Defendant's Exhibit DX 01079</b>	
	<b>15</b>	Stage 0: Product Concept Assessment Form Synopsis, <b>March 2, 1993</b> , DXL- 063198 thru 063202, <b>Defendant's Exhibits DX 01143</b>	
	<b>16</b>	Ditropan XI and Market Pricing, <b>Defendant's Exhibit DX 01151</b> , JJ-00447 thru JJ-00456	
	<b>17</b>	Harry C. Boghician (Portfolio), 5 pages <b>Defendant's Exhibit DX 1216 A</b>	
	<b>18</b>	In the United States District Court for the Northern District of West Virginia, ALZA Corporation, Plaintiff v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. Defendants, C.A. No.: 1:03CV61, Expert Report of James A. Forstner, <b>April 29, 2004</b> , <b>Defendant's Exhibit DX 01219</b>	
	<b>19</b>	Curriculum Vitae-Gordon L. Amidon, <b>Defendant's Exhibit DX 01226</b> , 93 pages	
	<b>20</b>	Fax Letter from Jeffrey I.D. Lewis to James H. Wallace, <b>Defendant's Exhibit DX 01245</b> , 2 pages	
	<b>21</b>	Curriculum Vitae, Stanley Kandzari, M.D. <b>Updated April 1, 2005</b> , <b>Defendant's Exhibit DX 1266 B</b> , 1page	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>22</b>	Experimental Formula Sheet-Sustained Release Oxybutynin Chloride Pellets, <b>MYLAN 1014435, Defendant's Exhibit DX 01403</b>	
	<b>23</b>	Australia Patents Act, "Complete Specification for Sustained Release Pharmaceutical Composition, 55 pages	
	<b>24</b>	Saks, S.R. MD, "Pharmacokinetics of OROS® and Oxybutynin", <i>ALZA Corporation Physician Advisory Board Meeting, October 9-11, 1998</i> , DXL-044580 thru 004591 <b>Defendant's Exhibit DX 1501</b>	
	<b>25</b>	Winkler, H.A. et al., "Treatment of Detrusor Instability with Oxybutynin Rectal Suppositories" <i>International Urogynecology Journal, 1998</i> , 9, 100-102, <b>Defendant's Exhibit DX 1503</b> , 3 pages	
	<b>26</b>	Massad, C.A. et al., "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride", <i>The Journal of Urology, 1992</i> , 148, 595-597, <b>Defendant's Exhibit DX 1504</b>	
	<b>27</b>	<b>Defendant's Exhibit DX 1507</b> , DXL084950 thru DXL084985	
	<b>28</b>	Projected Ditropan XL Net Trade Sales, <b>Defendant's Exhibit DX 1511</b> , 5 pages	
	<b>29</b>	Quarterly TRX Market Share and TRX Following Launch(Quarterly), <b>Defendant's Exhibits DX 1512</b> ,	
	<b>30</b>	Gupta, S. PhD., "New Pharmacokinetic Information on Ditropan® XL, <i>Physician Advisory Board Meeting, Medical Education Technologies Job # AZ11-0013</i> , <b>Defendant's Exhibit DX 1515C</b> , DXL 045275 thru 045313	
	<b>31</b>	Stage 0: Product Concept Assessment Form Synopsis, <b>March 2, 1993, Defendant's Exhibit DX 1517</b> , DXL 063216 thru 063222	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>32</b>	Final Report C-96-074-02 "Effect of Food on the Pharmacokinetics and Bioavailability of OROS® (oxybutynin chloride) relative to Ditopan®", <b>November 1997</b> , DXL-081963 thru 081999, <b>Defendant's Exhibit DX 1530</b>	
	<b>33</b>	Oxybutynin Chloride, <b>Defendant's Exhibit DX 1540</b> , DXL 050624 ,050505 thru 050516, 9 pages	
	<b>34</b>	Oxybutynin Chlroide, <b>Defendant's Exhibit DX 1541</b> , DXL 050625, 1 page	
	<b>35</b>	<b>Defendant's Exhibit DX 1542</b> , 1page	
	<b>36</b>	<b>Defendant's Exhibit DX 1543</b> , ALZA Expert 00267, 1 page	
	<b>37</b>	Genitourinary Smooth Muscle Relaxants, <i>American Hospital Formulary Service, 1997</i> , <b>Defendant's Exhibit DX 1544</b> , DXL 079384 thru DXL 0793387	
	<b>38</b>	Letter from Jeffrey I.D. Lewis to Nicholas A Peppas, Ph.D., <b>Defendant's Exhibits 1546</b> , 5 pages	
	<b>39</b>	In the United States District Court for the Southern District of Florida, Pfizer, Inc. and Alza Corporation, Plaintiffs, v. Andrx Corporation, Andrx Pharmaceuticals, inc., and Andrx Pharmaceuticals, LLC, Defendants, C.A. No.: 01-8636, Amended Complaint, <b>Defendant's Exhibit DX 1548</b> , 17 pages	
	<b>40</b>	Siepmann, J. et al., "HPMC-Matrices for Controlled Drug Delivery: A New Model Combining Diffusion, Swelling, and Dissolution Mechanisms and Predicting the Release Kinetics", <i>Pharmaceutical Research</i> , 1999, 16(11), 1748-1756, <b>Defendant's Exhibit DX 1551</b>	
	<b>41</b>	Siepmann, J. et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", <i>Journal of Pharmaceutical Sciences</i> , January 1999, 88(1), 65 thru 72, <b>Defendant's Exhibit DX 1552</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>42</b>	Baker, R., "Controlled Release of Biologically Active Agents", 1987, 1-21, <b>Defendant's Exhibit DX 1553</b>	
	<b>43</b>	'355 Claim 1 vs. Baichwal Example 15 Data, 1 page, <b>Defendant's Exhibit 1554</b>	
	<b>44</b>	'355 Claim 1 vs. Baichwal Example 15 vs. Example 1, 1 page, <b>Defendant's Exhibit 1557</b> ,	
	<b>45</b>	Fundamentals of Controlled Release and Pharmaceutical Engineering, Spring 1993, <b>Defendant's Exhibit DX 1558</b>	
	<b>46</b>	'355 Claim 1 vs. '355 Example 1 Data, <b>Defendant's Exhibit DX 1559</b> , 1 page	
	<b>47</b>	U.S. Pharmacopeia & National Formulary, <b>Defendant's Exhibit DX 1561</b> , 2232-2240	
	<b>48</b>	Figure 1 of the '355 Patent: Typical Release Curve for 24-Hour Controlled Release Data, <b>Defendant's Exhibit DX 1562, 1563</b> 2 pages	
	<b>49</b>	General Requirements for Tests and Assays, <b>Defendant's Exhibit DX 1566</b> , 1833 thru 1861	
	<b>49A</b>	Moore, K. et al., "Oxybutynin Hydrochloride (3mg) in the Treatment of Women with Idiopathic Detrusor Instability", <i>British Journal of Urology</i> , 1990, 66, 479-485, <b>Defendant's Exhibit DX 1570</b>	
	<b>50</b>	USP Dissolution Calibrator, Non-Disintegrating Type, <b>Defendant's Exhibit DX 1573</b> , 2 pages	
	<b>51</b>	Oxybutynin Chloride ER (OXYB-0262) Data, <b>Defendant's Exhibit DX 1580-DX 1586</b> , Mylan 0060307, 1 page	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>52</b>	Reviewer Guidance-Validation of Chromatographic Methods, <i>Center for Drug Evaluation and Research (CDER)</i> , November 1994, 1 thru 30, <b>Defendant's Exhibit 1588</b>	
	<b>53</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1589</b> , MYLAN 1014490-1014492	
	<b>54</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1590</b> , MYLAN 1014485-1014487	
	<b>55</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1591</b> , MYLAN 1014477-1014479	
	<b>56</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1592</b> , MYLAN 1014480-1014482	
	<b>57</b>	ALZA Corporation-Payments to Virginia Commonwealth University Data- <b>Defendant's Exhibit 1593</b> , DXL 085000-085017	
	<b>58</b>	Mylan 10 mg Product-Apparatus 2(Paddle) with Media Switch Data- <b>Defendant's Exhibit DX 1594-1598</b>	
	<b>59</b>	U.S. Pharmacopeia & National Formulary, <b>Defendant's Exhibit DX 1803</b> , 1128-1129	
	<b>60</b>	Baichwal Teaches the Conventional Wisdom Data- <b>Defendant's Exhibit DX 1804</b> , 1 page	
	<b>61</b>	Mylan 5mg Product Data- <b>Defendant's Exhibit DX 1805</b> , 7 pages	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	<b>62</b>	Mylan 10 mg Product Data-Defendant's Exhibit <b>DX 1806</b> , 4 pages
	<b>63</b>	Concentration Result Data-Defendant's Exhibit <b>DX 1808</b> , 1 page
	<b>64</b>	U.S. Pharmacopeia- The Official Compendia of Standards, <b>Defendant's Exhibit 1814</b> , 4 pages
	<b>65</b>	Mylan 10 mg Product, Mylan 5 mg Product Data- <b>Defendant's Exhibit DX 1816-1817</b>
	<b>66</b>	U.S. Pharmacopeia- The Official Compendia of Standards, <b>Defendant's Exhibit 1818</b> , 6-8, 2160-2165
	<b>67</b>	Mylan 10 mg Product Data- <b>Defendant's Exhibit DX 1819</b> , 1 page
	<b>68</b>	U.S. Pharmacopeia- The Official Compendia of Standards, <b>Defendant's Exhibit 1821</b> , 2513-2519
	<b>69</b>	Copy of CD- <b>Defendant's Exhibit DX 1822</b>
	<b>70</b>	'355 Claim 1 vs. Examples A and B Data- <b>Defendant's Exhibit 1823</b> , 1 page
	<b>71</b>	Data- <b>Defendant's Exhibit 1825</b> , 1 page
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>72</b>	Mylan Tablet Data-Defendant Exhibits 1827 thru 1831	
	<b>73</b>	5 mg Oral Solution Data-Defendant's Exhibit 1832-1833, 46 pages	
	<b>74</b>	Mylan Tablet Data-Defendant's Exhibit 1836, 1 page	
	<b>75</b>	Mylan Tablet Data-Defendant's Exhibit 1900-1901	
	<b>76</b>	Miyamoto, E. et al., "Physico-Chemical Properties of Oxybutynin", <i>Analysts, July 1994</i> , 119, 1489-1492, <b>Defendant's Exhibit 1902</b> , DXL 005871-005874	
	<b>77</b>	State of the Art: Colonic Absorption Studies, Defendant's Exhibit DX 2001, 1 page	
	<b>78</b>	Colonic Absorption Studies and Data-Defendant's Exhibit DX 2002	
	<b>79</b>	Wong, P.S.L. et al., "Osmotically Controlled Tablets", <i>Modified-Release Drug Delivery Technology, 2003</i> , 101-114 <b>Joint Exhibit 109</b>	
	<b>80</b>	ALZA: OROS® Oral Delivery Technology, <b>March 9, 2004</b> , <a href="http://www.alza.com/print/oros">http://www.alza.com/print/oros</a> , <b>Joint Exhibit 111</b> , 2 pages	
	<b>81</b>	Patent Information: DITROPAN XL®(oxybutynin chloride) Extended Release Tablet, <b>Joint Exhibit 112</b> , DXL 070943	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>82</b>	Douchamps, J. et al., "The Pharmacokinetics of Oxybutynin in Man", <i>Eur J. Clin Pharmacol</i> , 1988, 35, 515-520, <b>Joint Exhibit 116</b> , 5 pages	
	<b>83</b>	Cystrin® SR, Sustained Release Oxybutynin Hydrochloride, Development Pharmaceutics, March 9, 1994, PW 000225-PW 000280, <b>Joint Exhibit 130</b>	
	<b>84</b>	Patent Data, DXL 070941-070942, <b>Joint Exhibit 131</b>	
	<b>85</b>	The United States Pharmacopeia Convention, Inc. 1990, 1790-1799, <b>Joint Exhibit 133</b>	
	<b>86</b>	Oxybutynin/Official Monographs, <b>Joint Exhibit 134</b> , 1 page	
	<b>87</b>	The United States Pharmacopeia Convention, Inc., The Official Compendia of Standards, 2002, 2010-2022, <b>Joint Exhibit 135</b>	
	<b>88</b>	<b>Joint Exhibit 137</b> , 1578-1581	
	<b>89</b>	Van Bommel, E.M.G. et al., "Comparison of <i>In Vitro</i> and <i>In Vivo</i> Release Characteristics of Acetaminophen from Gradient Matrix Systems, <i>Biopharmaceutics &amp; Drug Disposition</i> , 1991, 12, 367-373, <b>Joint Exhibit 139</b>	
	<b>90</b>	Oxybutynin Chloride Extended-Release Tablets, 10 MG, Uniformity of Dosage Units (FP-OXYB10-CU-M) , 5514-5539, MYLAN 0065620-0065646, <b>Joint Exhibit 232</b>	
	<b>91</b>	Preik, M. et al., "Effect of Controlled-Release Delivery on the Pharmacokinetics of Oxybutynin at Different Dosages: Severity-Dependent Treatment of the Overactive Bladder", <i>BJU International</i> , 2004, 821-827, <b>Plaintiff's Exhibit 396</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<p>Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office</p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
92	Patent Data, <b>Plaintiff's Exhibit 40, 43, 53, 54, 58, 59</b> , 1 page each, 6 total pages	
93	Leesman, G.D. et al., "Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility", <i>Pharmacokinetics</i> , Chapter 6, 267-284, <b>Plaintiff's Exhibit 131</b>	
94	Patent Data, <b>Plaintiff's Exhibit 143</b> , 1 page	
95	Product Monograph, "Once-a-Day Ditropan® XL, <b>Plaintiff's Exhibits 157</b> , DXL-044976 thru DXL-045027	
96	Anderson, R.U. et al., "Once Daily Controlled Versus Immediate Release Oxybutynin Chloride for Urge Urinary Incontinence", <i>The Journal of Urology</i> , June 1999, 161, 1809-1812, <b>Plaintiff's Exhibit 197</b>	
97	Versi, E. MD, PhD. Et al., "Dry Mouth with Conventional and Controlled Release Oxybutynin in Urinary Incontinence", <i>Obstetrics &amp; Gynecology</i> , 2000, 95(5), 718-721, <b>Plaintiff's Exhibit 198</b>	
98	Appell, R.A. MD. et al., "Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study", <i>May Clin. Proc.</i> , 2001, 76, 358-363, <b>Plaintiff's Exhibit 199</b>	
99	OROS TDC-1 Meeting Minutes, November 23, 1993, DXL-027199-02713, <b>Plaintiff's Exhibit 203</b>	
100	Cystrin Cr-Release Rate Profile, August 14, 1998, DXL-017224-017225, <b>Plaintiff's Exhibit 213</b>	
101	Patent Data-DXL 016934, <b>Plaintiff's Exhibit 260</b>	
EXAMINER	DATE CONSIDERED	

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>102</b>	Gupta, S.K. PhD. et al., "Pharmacokinetics of an Oral Once-a-Day Controlled-Release Oxybutynin Formulation Compared with Immediate-Release Oxybutynin", <i>J. Clin. Pharmacol.</i> , 1999, 39, 289-296, DXL-023945-023952, <b>Plaintiff's Exhibit 261</b>	
	<b>103</b>	Patent Data, MYLAN 1008193-1008196, <b>Plaintiff's Exhibit 266</b>	
	<b>104</b>	Highlights of OROS TDC-1 Meeting, <b>June 28, 1993</b> , DXL 017162, <b>Plaintiff's Exhibit 287</b>	
	<b>105</b>	OROS TDC-1 Meeting Minutes- <b>September 17, 1993</b> , DXL 027224-027236, <b>Plaintiff's Exhibit 288</b>	
	<b>106</b>	Work Plan and Cost Estimate for Stage 2 Activities for OROS® Oxybutynin, DXL 043711-043715, <b>Plaintiff's Exhibit 289</b>	
	<b>107</b>	Commercial Assessment OROS/TTS TDC-1 Oxybutynin, Stage 3, <b>September 1995</b> , DXL 063416-063563, <b>Plaintiff's Exhibit 308</b>	
	<b>108</b>	OROS TDC-1 Meeting Minutes, <b>October 21, 1993</b> , DXL 027214-027215, <b>Plaintiff's Exhibit 309</b>	
	<b>109</b>	Sathyam, G. et al., "Effect of OROS® Controlled-Release Delivery on the Pharmacokinetics and Pharmacodynamics of Oxybutynin Chloride", <i>J. Clin. Pharmacol.</i> , 2001, 52, 409-417, DXL 051995-052003, <b>Plaintiff's Exhibit 315</b>	
	<b>110</b>	Buyse, G. et al., "Intravesical Pxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects Due to Reduced First Pass Metabolism", <i>The Journal of Urology</i> , 1998, 160, 892-896, <b>Plaintiff's Exhibit 323</b>	
	<b>111</b>	Diokno, A.C. et al., "Prospective, Randomized, Double-blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trail", <i>Mayo Clin Proc.</i> , 2003, 78, 687-695, <b>Plaintiff Exhibit 326</b>	
EXAMINER		DATE CONSIDERED	

<p>Form PTO-1449 Modified   List of Patent and Publications  Cited by Applicant  (Use several sheets if necessary)   U.S. Department of Commerce  Patent and Trademark Office</p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
112	Gupta, P. K. et al., "Oral Controlled-Release Delivery", <i>Treatise on Controlled Drug Delivery, 1992, PX329_0002-329_0058, Plaintiff's Exhibit 329</i>	
113	Dmochowski, R.R. et al., "Advancements in Pharmacologic Management of the Overactive Bladder", <i>Urology, 2000, 54(6A), 41-49, Plaintiff's Exhibit 391</i>	
114	Read, N.W. et al., "Gastrointestinal Dynamics and Pharmacology for the Optimum Design of Controlled-Release Oral Dosage Forms", <i>CRC Critical Reviews in Therapeutic Drug Carrier Systems, 1987, 4(3), 221-263, Plaintiff's Exhibits 397</i>	
115	Miyamoto, E. et al., "Physico-Chemical Properties of Oxybutynin", <i>Analyst, 1994, 119, 1489-1492, DXL 005871-005874</i>	
116	Modern Pharmaceutics, Oral Drug Delivery, Chapter 5, ALZA Research Library, DXL 043878 thru DXL 043926, <i>Plaintiff's Exhibit 403</i>	
117	Physicians' Desk Reference®, PDR®, 47 <sup>th</sup> Edition, 1993, 1377-1378, DXL 028121-DXL 028123, <i>Plaintiff's Exhibit 451</i>	
118	Longer, M.A. et al., "Sustained-Release Drug Delivery Systems", <i>Pharmaceutical Sciences, 1985, 92, 1644-1661, Plaintiff's Exhibit 462</i>	
119	Patent Data, JJ 00142 thru JJ 00281, <i>Plaintiff's Exhibit 464</i>	
120	Banker, G.S., "Pharmaceutical Applications of Controlled Release: An Overview of the Past, Present, and Future", <i>Medical Applications of Controlled Release, 1984, Volume II, 1-34, Plaintiff's Exhibit 467</i>	
121	Yu, L.X. et al., "Transport Approaches to the Biopharmaceutical Design of Oral Drug Delivery Systems: Prediction of Intestinal Absorption", <i>Advanced Drug Delivery Reviews, 1996, 19, 359-376, Plaintiff's Exhibit 471</i>	
EXAMINER	DATE CONSIDERED	

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
122	Lipka, E. et al., "Setting Bioequivalence Requirements fro Drug Development based on Preclinical Data: Optimizing Oral Drug Delivery Systems", <i>Journal of Controlled Release</i> , 1999, 62, 41-49, <b>Plaintiff's Exhibit 473</b>	
123	Lukkari, E. et al., "Effect of Food on the Bioavailability of Oxybutynin from a Controlled Release Tablet", <i>Eur. J. Clin. Pharmacol.</i> , 1996, 50, 221-223, <b>Plaintiff's Exhibit 482</b>	
124	Rocca, J. G. PhD. et al., "Oral Drug Delivery: Prospects & Challenges", <i>Drug Delivery Technology</i> , 2004, 4(4), 53-57, <b>Plaintiff's Exhibit 484</b>	
125	Waldeck, K. et al., "Comparison of Oxybutynin and its Active Metabolite, N-Desethyl-Oxybutynin, in the Human Detrusor and Parotid Gland", <i>The Journal of Urology</i> , 1997, 157, 1093-1097, <b>Plaintiff's Exhibit 486</b>	
126	Chancellor, M.B. Md, et al., "A Comparison of the Effects on Saliva Output of Oxybutynin Chloride and Tolterodine Tartrate", <i>Clinical Therapeutics</i> , 2001, 23(5), 753-760, <b>Plaintiff's Exhibit 488</b>	
127	Laboratory Notebook, Biomaterials & Drug Delivery Labs, <b>Plaintiff's Exhibit 491</b>	
128	Patent Data- <b>Plaintiff's Exhibit 494 (d)</b>	
129	Patent Data- <b>Plaintiff's Exhibit 495 (e)</b>	
130	Patent Data- <b>Plaintiff's Exhibit 496 (f)</b>	
131	Patent Data- <b>Plaintiff's Exhibit 497 (g)</b>	
EXAMINER	DATE CONSIDERED	

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<b>132</b>	Alza Corporation v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc, No: 1:03cv61-Supplemental Expert Report of Anthony Lowman, Lowman Video, <b>Plaintiff's Exhibit 498 (h)</b> , 1 page copy of the disc only
	<b>133</b>	Stage 0: Product Concept Assessment Form Synopsis, <b>March 2, 1993</b> , DXL- 016939 thru 016948, <b>Plaintiff's Exhibit 503</b>
	<b>134</b>	Translation of Finnish Package Insert (from Swedish language), DXL 012241-012243, <b>Plaintiff's Exhibit 506</b>
	<b>135</b>	Patent Data- JJ 02815 thru JJ 02817, <b>Plaintiff's Exhibit 536, 538</b>
	<b>136</b>	Patent Data- <b>Plaintiff's Exhibit 548, 549, 550, 551</b>
	<b>137</b>	Curriculum Vitae of Nicholas A. Peppas, 1- 113, <b>Plaintiff's Exhibit 552</b> ,
	<b>138</b>	General Information- In Vitro and In Vivo Evaluation, <i>The United States Pharmacopeia Convention, Inc.</i> , 2161, <b>Plaintiff's Exhibit 554</b>
	<b>139</b>	Patent Data-Drug Release Profile- <b>Plaintiff's Exhibit 555</b> , MYLAN 1014477-1014492
	<b>140</b>	Curriculum Vitae of Anthony M. Lowman, Ph.D., 15 pages, <b>Plaintiff's Exhibit 556</b>
	<b>141</b>	Chancellor, M.B. et al., "Spit Study to Compare Different Formulations of Oxybutynin", Accepted as Poster Presentation at 1999 AUA, <b>Plaintiff's Exhibit 561</b> , DXL 048067, <b>Plaintiff's Exhibit 561</b>

EXAMINER

DATE CONSIDERED

<p>Form PTO-1449 Modified             List of Patent and Publications            Cited by Applicant            (Use several sheets if necessary)             U.S. Department of Commerce            Patent and Trademark Office</p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>142</b>	Gittleman, M. et al., "Once-Daily Oxybutynin Chloride (Ditropan XL) in Patients on other Anticholinergic Medications", Accepted as Poster Presentation at 1999 AUA, <b>Plaintiff's Exhibit 562</b> , DXL 048068
	<b>143</b>	Sand, P. Md. et al., "Dose Titration with Once-Daily Oxybutynin Chloride (Ditropan XL) in Previously Treated and Naïve Patients", Accepted as Oral Presentation at 1999 ACOG, <b>Plaintiff's Exhibit 563</b> , DXL 048071
	<b>144</b>	Versi, E. Md. et al., "Improving Urge Incontinence Treatments by Decreasing Dry Mouth with Controlled-Release Oxybutynin (Ditropan XL), Accepted as Poster Presentation at 1999 ACOG, <b>Plaintiff's Exhibit 566</b> , DXL 048072
	<b>145</b>	Schmidt, R.A., "Efficacy of Controlled-Release Once-a-Day Oxybutynin Chloride for Urge Urinary Incontinence", <i>Division of Urology</i> , <b>Plaintiff's Exhibit 567</b> , DXL 048073
	<b>146</b>	Brown, J., "Comparison of tolerability and Efficacy of Once-a-Day vs. Immediate-Release Oxybutynin Chloride in Patients with Urge Urinary Incontinence", <b>1998</b> , <b>Plaintiff's Exhibit 569</b> , DXL 048078
	<b>147</b>	Michel, M.C., "A Benefit-Risk Assessment of Extended-Release Oxybutynin" <i>Drug Safety</i> , <b>2002</b> , 25(12), 867-876, <b>Plaintiff's Exhibit 570</b>
	<b>148</b>	Physicians' Desk Reference®, <b>1994</b> , 48 edition, 20, <b>Plaintiff's Exhibit 577</b>
	<b>149</b>	Oxybutynin Chloride Extended Release Tablets 10 mg, Finished Product Specifications, MYLAN 0046025-0046026, <b>Plaintiff's Exhibit 579</b>
	<b>150</b>	Patent Data-MYLAN 1006248-1006257, <b>Plaintiff's Exhibit 591</b>
	<b>151</b>	Patent Data- <b>Plaintiff's Exhibit 592, 593, 594, 595</b>

EXAMINER

DATE CONSIDERED

<p><b>Form PTO-1449 Modified</b></p> <p><b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)</p> <p><b>U.S. Department of Commerce Patent and Trademark Office</b></p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	<b>152</b>	Patent Data-Experimental Formula Sheet- MYLAN 1014435-1014466, <b>Plaintiff's Exhibit 596</b>
	<b>153</b>	Qureshi, S.A. et al., "Typical Variability in Drug Dissolution Testing: Study with USP and FDA Calibrator Tablets and a Marketed Drug (Glibenclamide) Product", <i>European Journal of Pharmaceutical Sciences</i> , 1999, 7, 249-258, <b>Plaintiff's Exhibits 598</b>
	<b>154</b>	Patent Data- <b>Plaintiff's Exhibit 602 thru 649</b>
	<b>155</b>	Curriculum Vitae- Michael B. Chancellor, M.D., 83 pages, <b>Plaintiff's Exhibit 650</b>
	<b>156</b>	Goldenberg, M.M. PhD. "An Extended Release Formulation of Oxybutynin Chloride for the Treatment of Overactive Urinary Bladder", <i>Clinical Therapeutics</i> , 1999, 21(4), 634-642, DXL 052302-052031, <b>Defendant's Exhibit 656</b>
	<b>157</b>	Ouslander, J.G. MD., "Management of Overactive Bladder", <i>The New England Journal of Medicine</i> , 2004, 350, 786-799, <b>Plaintiff's Exhibit 664</b>
	<b>159</b>	Abrahamsson, B. et al., "Absorption, Gastrointestinal Transit, and Tablet Erosion of Felodipine Extended-Release (ER) Tablets", <i>Pharmaceutical research</i> , 1993, 10(5), 709-714
	<b>160</b>	Artursson, P., "Epithelial Transport of Drugs in Cell Culture. I: A Model for Studying the Passive Diffusion of Drugs over Intestinal Absorptive (Caco-2) Cells", <i>Journal of Pharmaceutical Sciences</i> , June 1990, 79(6), 476-482
	<b>161</b>	Chao, S.T. et al., "Effect of Food on Bioavailability of Pseudoephedrine and Brompheniramine Administered from a Gastrointestinal Therapeutic System", <i>Journal of Pharmaceutical Sciences</i> , 1991, 80(5), 432-435
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>162</b>	Chung, M. PhD. et al. "Clinical Pharmacokinetics of Nifedipine Gastrointestinal Therapeutic System", <i>The American Journal of Medicine</i> , 1987, 83, 10-14	
	<b>163</b>	Davis, S.S. et al., "Relationship between the rate of Appearance of Oxprenolol in the Systemic Circulation and the Location of an Oxprenolol Oros 16/260 Drug Delivery System within the Gastrointestinal Tract as Determined by Scintigraphy", <i>Br. J. Clin. Pharmac.</i> , 1988, 26, 435-443	
	<b>164</b>	Harder, S. et al., "Ciprofloxacin Absorption in Different Regions of the Human Gastrointestinal Tract. Investigations with the hf-Capsule", <i>Br. J. Clin. Pharmac.</i> , 1990, 30, 35-39	
	<b>165</b>	Hirtz, J., "The Absorption Window; Fact or Fiction?", <i>Pharmacy International</i> , 1984, 175-178	
	<b>166</b>	Marathe, P.H. et al., "Absorption and Presystemic Metabolism of Nefazodone Administered at Different Regions in the Gastrointestinal Tract of Humans", <i>Pharmaceutical Research</i> , 1995, 12(11), 1716-1721	
	<b>167</b>	Riley, S.A. et al., "Absorption of Polar Drugs following Caecal Instillation in Healthy Volunteers", <i>Aliment Pharmacol Ther.</i> , 1992, 6, 701-706	
	<b>168</b>	Sandberg, A. et al., "Steady-State Bioavailability and Day-to-Day Variability of a Multiple-Unit (CR/ZOK) and a Single-Unit (OROS) delivery System of Metoprolol after Once-Daily Dosing", <i>Pharmaceutical Research</i> , 1993, 10(1), 28-34	
	<b>169</b>	Stiehl, A. et al., "Colonic Absorption of Ursodeoxycholic Acid in Man", 42, 323-325	
	<b>170</b>	Wilding, I.R. et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation", <i>Pharmaceutical Research</i> , 1992, 9(5), 654-657	
	<b>171</b>	Williams, M.F. et al., "Influence of Gastrointestinal Site of Drug Delivery on the Absorption Characteristics of Ranitidine", <i>Pharmaceutical Research</i> , 1992, 9(9), 1190-1194	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>172</b>	Wilson, C.G. et al., "Bimodal release of Ibuprofen in a Sustained-Release Formulation: A Scintigraphic and Pharmacokinetic Open Study in Healthy Volunteers under Different Conditions of Food Intake", <i>International Journal of Pharmaceutics</i> , 1989, 50, 155-161	
	<b>173</b>	Antonin, K-H., "Other Methods in Studying Colonic Drug Absorption", Chapter 5, 89-107	
	<b>174</b>	Antonin, K.H. et al., "Evaluation of the Colonic Drug Absorption in Patients with an Artificial Intestinal Stoma and by Colonoscopy in Normal Volunteers", <i>National Library of Medicine</i> , 39-52	
	<b>175</b>	Bieck, P.R., "Drug Absorption from the Human Colon", <i>Acta Pharm Technol</i> , 1987, 33, 109-114	
	<b>176</b>	Davis, S.S., "Assessment of Gastrointestinal Transit and Drug Absorption", <i>Drug Delivery and its Therapeutic Application</i> , 1989, 9, 89-101	
	<b>177</b>	Hirtz, J., "Intubation Techniques for the Study of the Absorption of Drugs in Man", <i>National Library of Medicine</i> , 3-12	
	<b>178</b>	Hirtz, J., "The Gastrointestinal Absorption of Drugs in Man: A Review of Current Concepts and Methods of Investigation", <i>Br. J. Clin. Pharmac.</i> , 1985, 19, 77S-83S	
	<b>179</b>	Schuster, O. et al., "Course of Development of the HF-Capsule-Variations and Method-Related Typical Findings", <i>National Library of Medicine</i> , 28-38	
	<b>180</b>	Colonic Absorption Review Articles, <b>Defendant's Exhibit DX 2003</b> , 1 page	
	<b>181</b>	Fara, J.W., "Colonic Drug Absorption and Metabolism", <i>Novel Drug Delivery and its Therapeutic Application</i> , 1989, 10, 103-112, <b>Defendant's Exhibit DX 2004</b>	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>182</b>	Summary of Dr. Dmochowski's ALZA Contracts, <b>Defendant's Exhibit DX 2005</b>	
	<b>183</b>	Summary of Dr. Chancellor Contracts, <b>Defendant's Exhibit DX 2006</b>	
	<b>184</b>	Alza Total Payments to Dr. Chancellor, <b>Defendant's Exhibit DX 2007 and DX 2007 A</b>	
	<b>185</b>	Articles Regarding First-Pass Metabolisms, <b>Defendant's Exhibit DX 2008</b> , 1 page	
	<b>186</b>	Articles Regarding Reduced Side Effects from Non-Oral Administration, <b>Defendant's Exhibit DX 2009</b> , 1 page	
	<b>187</b>	Aaltonen, L. et al., "Antimuscarinic Activity of Oxybutynin in the Human Plasma Quantitated by a Radioreceptor Assay", <i>Acta Pharmacol. Et Toxicol.</i> , 1984, 55, 100-103	
	<b>188</b>	Hughes, K.M. et al., "Measurement of Oxybutynin and its N-Desethyl Metabolite in Plasma and its Application to Pharmacokinetic Studies in Young, Elderly and Frail Elderly Volunteers", <i>Xenobiotica</i> , 1992, 22(7), 859-869	
	<b>189</b>	Abstracts of the 1 <sup>st</sup> Congress of the European Association for Clinical Pharmacology and Therapeutics, 1995, <i>Therapie</i> , 65-68, <b>Plaintiff's Exhibit 485</b>	
	<b>190</b>	Madersbacher, H. Md. et al, "Control of Detrusor Hyperreflexia by the Intravesical Instillation of Oxybutynine Hydrochloride", <i>Paraplegia</i> , 1991, 29, 84-90	
	<b>191</b>	Ditropian XI, Prescribing Information, <b>Joint Exhibit 239</b> , 2 pages	
EXAMINER		DATE CONSIDERED	

<p><b>Form PTO-1449 Modified</b></p> <p><b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)</p> <p><b>U.S. Department of Commerce Patent and Trademark Office</b></p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
192	OROS Oxybutynin Release Rates Patent Data- <b>Joint Exhibit 27</b>	
193	OROS Oxybutynin Release Rates Patent Data- <b>Joint Exhibit 28</b>	
194	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 29</b>	
195	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 30</b>	
196	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 31</b>	
197	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 32</b>	
198	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 33</b>	
199	OROS Oxybutynin Release Rates Patent Data Patent Data- <b>Joint Exhibit 35</b>	
200	Appendix D-List of Documents Reviewed- <b>Joint Exhibit 47</b>	
201	Alza Corp. v. Mylan, C.A. # 1:03CV61, Expert Report of Dr. Gordon Amidon, Appendix J: Photo of Different Dosage Forms CD, <b>Joint Exhibit 53</b>	
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	

Form PTO-1449 Modified		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>202</b>	Lish, P.M., "Oxybutynin-A Musculotropic Antispasmodic Drug with Moderate Anticholinergic Action", <i>Mead Johnson Research Center</i> , <b>1964</b> , 467-488, DXL 014384-014406, <b>Joint Exhibit 54</b>	
	<b>203</b>	Experimental Formula Sheet Patent Data- MYLAN 1014326-1014370, <b>Joint Exhibit 55</b>	
	<b>204</b>	Declaration of Dr. William Barr, <b>Joint Exhibit 56</b> , 7 pages	
	<b>205</b>	Declaration of Dr. Patrick S.L. Wong, <b>Joint Exhibit 57</b> , 14 pages	
	<b>206</b>	Draft Annotated Physician Insert-DITROPAN® XL, DXL 072395-DXL 072407, <b>Joint Exhibit 78</b>	
	<b>207</b>	Rovner, E.S., et al., "Once-Daily, Extended-Release Formulations of Antimuscarinic Agents in the Treatment of Overactive Bladder: A Review", <i>European Urology</i> , <b>2002</b> , 41, 6-14, <b>Joint Exhibit 84</b>	
	<b>208</b>	Guidance for Industry, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In/Vitro/In Vivo Correlations, <i>U.S. Dept. of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research</i> , <b>September 1997</b> , 1-24, <b>Joint Exhibit 86</b>	
	<b>209</b>	Pitsiu, M. et al., "A Semiparametric Deconvolution Model to Establish in Vivo-In Vitro Correlation Applied to OROS Oxybutynin", <i>Journal of Pharmaceutical Sciences</i> , <b>2001</b> , 90(6), 702-712, <b>Joint Exhibit 89</b>	
	<b>210</b>	Barr Affidavit, 1-23, <b>Joint Exhibit 90</b>	
	<b>211</b>	Letter from S. Wayne Talton to Gary J. Buehler, re: Oxybutynin Chloride Extended-Release Tablets, 10mg and 76-644 Response to Agency Correspondence dated December 8, 2003, MYLAN 0978814-097835 w attached patent data, <b>Joint Exhibit 91</b>	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>212</b>	Theeuwes, F., "Evolution and Design of Rate Controlled Osmotic Forms", <i>Current Medical Research and Opinion</i> , 1983, 8(2), 20-27, <b>Joint Exhibit 93</b>	
	<b>213</b>	Theeuwes, F., et al. "Systems for Triggered, Pulsed, and Programmed Drug Delivery", <i>Annals New York Academy of Science</i> , 428-440, <b>Joint Exhibit 94</b>	
	<b>214</b>	Peters, K.M. et al., "Urinary Incontinence", 685-688, <b>Joint Exhibit 95</b>	
	<b>215</b>	Yarker, Y.E. et al., "Oxybutynin-A review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Use in Detrusor Instability", <i>Drug and Aging</i> , 1993, 3, 243-262, <b>Joint Exhibit 96</b>	
	<b>215A</b>	Hughes, K.M. et al., "Measurement of Oxybutynin and its N-Desethyl Metabolite in Plasma, and its Application to Pharmacokinetic Studies in Young, Elderly and Frail Elderly Volunteers", <i>Xenobiotica</i> , 1992, 22(7), 859-869, <b>Joint Exhibit 97</b>	
	<b>216</b>	Robinson, T.G. et al., "Drugs in Focus: Oxybutynin Hydrochloride", <i>Prescribers' Journal</i> , 1994, 34(1), 27-31, <b>Joint Exhibit 98</b>	
	<b>217</b>	Katori, N. et al., "Estimation of Agitation Intensity in the GI Tract in Humans and Dogs Based on <i>in Vitro/in Vivo</i> Correlation", <i>Pharmaceutical Research</i> , 1995, 12(2), 237-243, <b>Joint Exhibit 99</b>	
	<b>218</b>	Lukkari, E. et al., "Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled-Release Tablet", <i>Pharmacology &amp; Toxicology</i> , 1997, 81, 31-34, DXL 005964-005967 <b>Joint Exhibit 101</b>	
	<b>219</b>	Declaration of Dr. Patrick S.L. Wong, <b>Joint Exhibit 107</b> , 28 pages	
	<b>220</b>	Declaration of Dr. William Barr, <b>Joint Exhibit 108</b>	
	<b>221</b>	Patent Data-Ditropan XL 2003 OE/2004BP/2005 Forecast, JJ 00497-00577, <b>Plaintiff's Exhibit 139</b>	
EXAMINER		DATE CONSIDERED	

<p>Form PTO-1449 Modified</p> <p>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>222</b>	Collas, D. et al., "The Pharmacokinetic Properties of Rectal Oxybutynin- a Possible Alternative to Intravesical Administration", <i>Neurourology and Urodynamics</i> , 1997, 16(5), 346-347
	<b>223</b>	Madersbacher, M. et al., "Intravesical Application of Oxybutynine: Mode of Action in Controlling Detrusor-Hyperreflexia", <i>Dept. Urology, Univ. Hosp. Innsbruck and Rehab Center</i> , 375-376
	<b>224</b>	Mizunaga, M, Md. et al., "Intravesical Instillation of Oxybutynin Hydrochloride Therapy for Patients with a Neuropathic Bladder", <i>Paraplegia</i> , 1994, 32, 25-29
	<b>225</b>	Weese, D.L. et al., "Intravesical Oxybutynin Chloride: Experience with 42 Patients", <i>Urology</i> , June 1993, 41(6), 527-530
	<b>226</b>	O'Flynn, K.J. et al., "Intravesical Instillation of Oxybutynin Hydrochloride for Detrusor Hyper-Reflexia", <i>British Journal of Urology</i> , 1993, 72, 566-570
	<b>227</b>	Remington's Pharmaceutical Sciences, "Pharmacokinetic Models", 36, 726
	<b>228</b>	Lukkari, E., "Clinical Pharmacology of Oxybutynin, with Special Reference to Pharmacokinetics and Interactions", <i>Department of Clinical Pharmacology</i> , 1997, 1-50, PW 000281-000331
	<b>229</b>	Nilsson, C.G. et al. "Comparison of a 10-mg Controlled Release Oxybutynin Tablet with a 5-mg Oxybutynin Tablet in Urge Incontinent Patients", <i>Neurourology and Urodynamics</i> , 1997, 16, 533-542, DXL 012130-012139
	<b>230</b>	"Cystrin CR Launched in Finland for Urinary Incontinence", <i>Doctor's Guide to Medical &amp; Other News</i> , <a href="http://www.pslnet.com">http://www.pslnet.com</a> , May 7, 1998, 2 pages
	<b>231</b>	Fincher, J.H., "Particle Size of Drugs and its relationship to Absorption and Activity", <i>J. Pharm. Sci.</i> , 1968, 57, 1825-1835

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>232</b>	King, R.E. PhD. et al., "Oral Solid Dosage Forms", <i>Pharm. Sci. by Remington</i> , 17 <sup>th</sup> Ed., Ch. 90, pp. 1603-1625 (1985), published by Mack Publishing	
	<b>233</b>	Linhardt, R.J., "Biodegradable Polymers for Controlled Release of Drugs", Edited by M. Rosoff, Ch 2, pp. 53-95 (1989)	
	<b>233A</b>	Riva, D. et al., "Oxybutynin Chloride in the Treatment of female Idiopathic ladder Instability, <i>Clin. Exp. Obst. Gyn</i> , 1984, 37-42	
	<b>234</b>	Coleman, M.M et al., "A Practical Guide to Polymer Miscibilit", <i>Polymers</i> , 31, 1187-1231 (1990)	
	<b>235</b>	Drug Carrier Systems, by Roerdink et al., vol. 9, pp. 57-109 (1989)	
	<b>236</b>	Leong, K.W. et al., "Polymeric Controlled Drug Delivery", <i>Advanced Drug Delivery Reviews.</i> , vol 1, 199-233 (1987)	
	<b>237</b>	Handbook of Common Polymers, Compiled by Roff et al., (1971), published by CRC Press, 72-81	
	<b>238</b>	Wurster, D.E., "Air-Suspension Technique of Coating Drug Particles," <i>Journal of the American Pharmaceutical Association</i> , 48, 451-454 (Aug. 1959)	
	<b>239</b>	Wurster, D.E., "Preparation of Compressed Tablet Granulations by the Air-Suspension Technique II,", <i>Journal of the American Pharmaceutical Association</i> , 49, 82-84 (Feb.1960)	
	<b>240</b>	Pharmaceutical Sciences by Remington, 14 <sup>th</sup> Ed., pp. 1626-1680 (1970), published by Mack Publishing Co.	
	<b>241</b>	Database WPI, Derwent Publication Ltd., London, GB, AN 94-031722, XP002096607	
EXAMINER		DATE CONSIDERED	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>242</b>	Database WPI, Derwent Publication Ltd., London, GB, AN 94-068306, XP002096606	
	<b>243</b>	Gupta, S.K. et al., "Evidence for Site-Specific Presystemic Metabolism of Oxybutynin Following Oral Administration," <i>Clinical Pharmacology &amp; Therapeutics</i> , 61, 2, 1997, p. 227, XP002099744	
	<b>244</b>	In the United States District Court for the Northern District of California, Alza Corporation, Plaintiff v. Impax Laboratories, Defendant, Case No. C-03-4032-VRW and C-03-4795, Decision Not to Dismiss California Declaratory Judgment Action, <b>No Date</b>	
	<b>245</b>	IMPAX Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride, 15 mg. Tablets w/Appendix, <b>July 25, 2003</b>	
	<b>246</b>	IMPAX Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride, 5 and 10 mg. Tablets w/Appendix, <b>August 19, 2003</b>	
	<b>247</b>	In the United States District Court for the Northern District of California, Oakland Division, Case No. C-03-04032, Complaint for Patent Infringement w/Exhibit A, <b>September 4, 2003</b>	
	<b>248</b>	In the United States District Court for the Northern District of California, Oakland Division, Case No. C-03-04032, Answer, Affirmative Defenses and Counterclaims of IMPAX Laboratories, Inc., <b>October 1, 2003</b>	
	<b>249</b>	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Reply to Defendant IMPAX Laboratories, Inc.'s Counterclaims, <b>November 13, 2003</b>	
	<b>250</b>	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, IMPAX'S Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-8), <b>May 20, 2004</b>	
	<b>251</b>	In the United States District Court for the Northern District of California, Case No. C-03-4032 VRW, Order, <b>No Date</b>	
	<b>252</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Constructors, <b>December 15, 2004</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>253</b>	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, IMPAX'S Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-8), <b>May 20, 2004</b>	
	<b>254</b>	In the United States District Court for the Northern District of California, Case No. C-03-4032 VRW, Order, <b>No Date</b>	
	<b>255</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Constructions, <b>December 15, 2004</b>	
	<b>256</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of Nicholas A. Peppas in Support of Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Construction w/Exhibit A, <b>December 15, 2004</b>	
	<b>257</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of David Eiseman in Support of Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Construction w/Exhibits A-F, <b>December 15, 2004</b>	
	<b>258</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Objections and Responses to IMPAX Laboratories, Inc.'s First Set of Interrogatories, <b>January 10, 2005</b>	
	<b>259</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Supplemental Opening Memorandum of Law in Support of Claim Construction w/Exhibits A-J, <b>January 13, 2005</b>	
	<b>260</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Defendant IMPAX Laboratories Inc.'s Responsive Claim Construction Brief, <b>March 10, 2005</b>	
	<b>261</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of Mark I. Koffsky in Support of Defendant IMPAX Laboratories Inc.'s Responsive Claim Construction Brief, w/Exhibits A-B, <b>March 10, 2005</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	<b>265</b>	4,008,719	02/22/77	Theeuwes, et al.	128	260
	<b>266</b>	4,783,337	11/08/88	Wong, et al.	424	468
	<b>267</b>	5,135,757	08/04/92	Baichwal, et al.	434	465
	<b>268</b>	5,178,868	01/12/93	Malmqvist-Granlund, et al.	424	490
	<b>269</b>	5,407,686	04/18/95	Patel, et al.	424	468
	<b>270</b>	5,455,046	10/03/95	Baichwal	424	457
	<b>271</b>	5,532,278	07/02/96	Aberg, et al.	514	617
	<b>272</b>	6,124,355	09/26/00	Guittard, et al.	514	534

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>273</b>	AU 47732/90	07/12/90	Australia	X(Abstract)	
	<b>274</b>	WO 96/37202	11/28/96	PCT		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	<b>275</b>	4,519,801	05/28/85	Edgren	604	892
	<b>276</b>	4,612,008	09/16/86	Wong, et al.	604	892
	<b>277</b>	4,994,276	02/19/91	Baichwal, et al.	424	440
	<b>278</b>	5,082,668	01/21/92	Wong, et al.	424	473
	<b>279</b>	5,128,143	07/07/92	Baichwal, et al.	424	464
	<b>280</b>	5,330,766	07/19/94	Morella, et al.	424	490
	<b>281</b>	5,399,359	03/21/95	Baichwal	424	464
	<b>282</b>	5,498,422	03/12/96	Nakamichi, et al.	424	451
	<b>283</b>	5,674,895	10/07/97	Guittard, et al.	514	534
	<b>284</b>	5,811,126	09/22/98	Krishnamurthy	424	498
	<b>285</b>	5,840,754	11/24/98	Guittard, et al.	514	534
	<b>286</b>	5,912,268	06/15/99	Guittard, et al.	514	534
	<b>287</b>	6,262,115 B1	07/17/01	Guittard, et al.	514	534

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>288</b>	WO 96/37202	11/28/96	PCT		

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>289</b>	MYLAN Pharmaceuticals Inc. Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride 10 mg. Tablets, <b>March 19, 2003</b>	
	<b>290</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Complaint for Patent Infringement (ALZA) W/Exhibit A, <b>May 2, 2003</b>	
	<b>291</b>	MYLAN Pharmaceuticals Inc. Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride 5 mg. Tablets, <b>May 21, 2003</b>	
	<b>292</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Answer, Defenses and Counterclaims of Defendant Mylan Laboratories Inc., <b>May 27, 2003</b>	
	<b>293</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Reply to MYLAN Pharmaceuticals Inc.'s Counterclaims Filed in Consolidated Action 1:03CV158, <b>July 30, 2003</b>	
	<b>294</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Objections and Response to Plaintiff's First Set of Interrogatories, <b>September 18, 2003</b>	
	<b>295</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's First Set of Interrogatories, <b>September 29, 2003</b>	
	<b>296</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Second Set of Interrogatories, <b>October 8, 2003</b>	
	<b>297</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Third Set of Interrogatories, <b>December 18, 2003</b>	
	<b>298</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Fourth Set of Interrogatories, <b>February 17, 2004</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
	Confirmation No. <b>8204</b>	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>299</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Response to Mylan's Fifth Set of Interrogatories, <b>March 4, 2004</b>
	<b>300</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Supplemental Response to Mylan's Fifth Set of Interrogatories (Interrogatory No. 12), <b>March 19, 2004</b>
	<b>301</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Objections and Supplemental Responses to Plaintiff's first Set of Interrogatories, <b>March 21, 2004</b>
	<b>302</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Second Supplemental Response to Mylan's Fifth Set of Interrogatories (Interrogatory No. 8), <b>March 26, 2004</b>
	<b>303</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's First Supplemental Response to Mylan's Third Set of Interrogatories (No. 6), <b>April 12, 2004</b>
	<b>304</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Pretrial Memorandum, <b>December 2, 2004</b>
	<b>305</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Order Construing Claims and Denying Summary Judgment, <b>December 7, 2004</b>
	<b>306</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA's) Pre-Trial Memorandum (w/Exhibits A-C),
	<b>307</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, Markman Hearing Transcript, <b>December 29, 2004</b>
	<b>308</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Notice Pursuant to 35 U.S.C. § 282, <b>January 7, 2005</b>

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>309</b>	United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Trial Transcript, <b>April 18, 2005</b>	
	<b>310</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Post-Trial Brief, with Exhibits A and B, <b>May 6, 2005</b>	
	<b>311</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA) Post-Trial Reply Memorandum, <b>June 1, 2005</b>	
	<b>312</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Post-Trial Reply Brief, <b>June 1, 2005</b>	
	<b>313</b>	Mylan Letter to Judge Irene M. Keely regarding ALZA's arguments in its Post Trial Reply Brief, 1 page, <b>June 15, 2005</b>	
	<b>314</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Notice of Paragraph IV Certification US Patent 6,919,092 Oxybutynin Chloride Extended Release Tablets, 5 mg. and 10 mg. b, <b>July 22, 2005</b>	
	<b>315</b>	In United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA) Post-Trial Reply Memorandum (Corrected), <b>No Date</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>316</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Supplemental Invalidity Contentions, Mylan's Supplemental Contentions Supporting the Invalidity of U.S. Patent No. 6,124,355, <b>January 29, 2003</b> , 26 pages	
	<b>317</b>	In the United States District Court for the Northern District of West Virginia, at Clarksburg, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Contentions Supporting the Invalidity of U.S. Patent No. 6,124,355, <b>December 29, 2003</b>	
	<b>318</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment(#3) of Invalidity for Indefiniteness Under <i>Honeywell</i> , <b>July 14, 2004</b> , 12 pages	
	<b>319</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Opposition to Defendant's Motion for Summary Judgment on Invalidity for Indefiniteness Under <i>Honeywell</i> (#3), <b>August 27, 2004</b> , 15 pages	
	<b>320</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Summary Judgment (#3) of Invalidity for Indefiniteness Under <i>Honeywell</i> , <b>September 17, 2004</b> , 14 pages	
	<b>321</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue", With Attached Exhibit A, <b>July 14, 2004</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>322</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#2) of Invalidity based on Inherent Anticipation, <b>July 14, 2004</b> , With attached Exhibits A & B	
	<b>323</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#5) of Invalidity Based Upon a Lack of Novelty over the Prior Art, Memorandum in Support of Mylan's Motion for Summary Judgment (#5) of Invalidity Based upon a Lack of Novelty over the Prior Art, <b>July 14, 2004</b>	
	<b>324</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Opposition to Defendant's Motion for Summary Judgment (#5) of Invalidity based Upon a Supposed Lack of Novelty over the Prior Art, <b>August 27, 2004</b>	
	<b>325</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#5) of Invalidity Based Upon a Lack of Novelty over the Prior Art, <b>September 17, 2004</b> , with attached Exhibits A, B	
	<b>326</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Opening Memorandum of Law in Support of Claim Construction, <b>July 14, 2004</b> , with attached Exhibits A thru I	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	327	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Memorandum in Reply to Defendants' Responsive Claim Construction Memorandum, <b>September 3, 2004</b> , with attached Exhibits N thru S	
	328	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Response to Defendants' "Markman" Claim Construction Memorandum, <b>August 20, 2004</b> , with attached Exhibits J thru M	
	329	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's "Markman" Reply Memorandum, <b>September 3, 2004</b>	
	329 A	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue, <b>September 3, 2004</b>	
	330	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's "Markman" Claim Construction Memorandum, with attached Exhibits A thru C, <b>July 14, 2004</b>	
	331	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Response to Alza's Claim Construction Memorandum, <b>August 20, 2004</b> , with attached Exhibits A, B.	
	332	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#2) of Invalidity Based on Inherent Anticipation, <b>July 14, 2004</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>333</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue, <b>July 14, 2004</b> , w/attached Exhibit A	
	<b>334</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#5) of Invalidity based upon Lack of Novelty over the Prior Art, <b>July 14, 2004</b>	
	<b>335</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Combined Memorandum in Opposition to Defendant's Motion for Summary Judgment on the Threshold Priority Issue (#1) and Invalidity based on Inherent Anticipation, <b>August 20, 2004</b> , with attached Exhibits A,B	
	<b>336</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#2) of Invalidity Based on Inherent Anticipation, <b>September 3, 2004</b>	
	<b>337</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Memorandum in Reply to Defendant's Responsive Claim Construction Memorandum, <b>September 7, 2004</b>	
	<b>338</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Supplemental Briefing on <i>Kennecott</i> and Alleged "Inherent Written Description", <b>November 2, 2004</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>339</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Response to Mylan's Supplemental Briefing on <i>Kennecott</i> and Alleged "Inherent Written Description", <b>November 13, 2004</b>	
	<b>340</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff's Pre-Trial Memorandum, <b>December 22, 2004</b>	
	<b>341</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Memorandum in Support of its Motion for Reconsideration, <b>December 23, 2004</b>	
	<b>342</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Reconsideration of the Court's Ruling on Summary Judgments # 1 and #2, <b>December 24, 2004</b>	
	<b>343</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Reconsideration of the Court's Ruling on Summary Judgments #1 and #2, Mylan's Memorandum in Support of its Motion for Reconsideration, <b>January 24, 2005</b>	
	<b>344</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Reconsideration, <b>January 31, 2005</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>346</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff's Post Trial Memorandum(Corrected) <b>June 1, 2005</b>	
	<b>347</b>	Ditropan XL NTS: Projections and Annuals, <b>Defendant's Exhibit DX 2012</b>	
	<b>348</b>	Letter from Michael B. Chancellor, M.D. to Richard McCormick-Re: ALZA v. Mylan [Ditropan XL], <b>Defendant's Exhibit DX 2016</b>	
	<b>349</b>	Quarterly TX Market Share (Updated) , <b>Defendant's Exhibit DX 2017</b>	
	<b>350</b>	Market Share Trends, <b>Defendant's Exhibit DX 2018</b>	
	<b>351</b>	J & J Worldwide Advertising Group media Budget Control Record(MBCR), Ditropan, <b>Defendant's Exhibit DX 2019</b>	
	<b>352</b>	DX 2020-Articles teaching that a Lower Dose of Oxybutynin is Effective and has Fewer Side Effects, <b>Defendant's Exhibit DX 2020</b>	
	<b>353</b>	Ditropan XL: BMEs as a Percent of Net Trade Sales, <b>Defendant's Exhibit DX 2024</b>	
	<b>354</b>	Alza Corporation Physician Advisory Board Meeting, Phoenix, AZ, 1998, <b>Defendants Exhibit DX 2029</b>	
	<b>355</b>	Ditropan-XI TRX Market Share Compared to Rebates (%NTS), <b>Defendants Exhibit DX 2025</b>	
	<b>356</b>	Chancellor, M.B. MD., "What is Really New in Overactive Bladder?, <b>February 25, 2004, Defendant's Exhibit DX 2038</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>ALZA-0142</b>	Application No. <b>10/645,467</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>George V. Guittard, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>August 20, 2003</b>	Group <b>1616</b>
		Confirmation No. <b>8204</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>357</b>	AWP Price Per Day: TID Oxy Products, <b>Defendant's Exhibit's DX 2039</b>	
	<b>358</b>	Ditropan ® Xl, Recommendation for Additional Clinical Study, <b>Defendant's Exhibit 2056,</b>	
	<b>359</b>	Ditropan XL: NTS Compared to Profits, <b>Defendant's Exhibit DX 2061</b>	
	<b>360</b>	Ditropan XL Profits Compared to J & J Investment, <b>Defendant's Exhibit DX 2062</b>	
	<b>361</b>	Ditropan XL Financial Data, <b>Defendant's Exhibits DX 2063</b>	
	<b>362</b>	Ditropan-XL TRX Market Share Compared to BME/Selling (%NTS), <b>Defendant's Exhibits DX 2065</b>	
	<b>363</b>	Ditropan Xl ® vs Detrol ® Spit Study, Post-Launch (Stage 5), <b>Defendant's Exhibit DX 2067</b>	
	<b>364</b>	Physicians' Desk Reference, PDR®, 42 Edition, <b>1988</b> , Ditropan Tablets and Syrup	
EXAMINER		DATE CONSIDERED	